🟠 Moderate Evidence
Caffeine accounts for only 1–2% of coffee by weight, yet the beverage’s effects on human health have long been attributed primarily to this single compound. A new controlled microbiome study reveals that coffee’s non-caffeine constituents—particularly chlorogenic acids and melanoidins formed during roasting—drive measurable shifts in gut bacterial composition, suggesting the other 98–99% of the coffee matrix plays a central role in how the beverage influences the microbiome. The findings challenge the caffeine-centric view of coffee’s biological action and point toward polyphenol-mediated pathways as drivers of microbiome remodeling.
Key takeaways
- Chlorogenic acids and melanoidins—not caffeine—appear to be the primary drivers of coffee’s effect on gut bacteria, as decaffeinated coffee produced identical microbiome shifts
- Daily coffee drinkers showed increased levels of Cryptobacterium species, which produce indoles that support intestinal barrier integrity
- The same drinkers experienced a decrease in indole-3-propionic acid (IPA), a bacterial metabolite linked to lower type 2 diabetes risk and stronger gut barrier function—a potentially unfavorable shift
- The study was small (N=62) and exploratory; findings require replication in larger, longer-term populations
Study at a Glance
| Source | APC Microbiome Ireland research group |
| Study type | Controlled intervention (5-week protocol) |
| Sample size | N = 62 (31 daily drinkers, 31 non-drinkers) |
| Population | Adults: habitual coffee drinkers (3–5 cups/day) vs. non-drinkers |
| Country | Ireland |
Coffee Composition: Caffeine vs. Bioactive Compounds
Percentage breakdown of coffee by weight, showing caffeine’s minimal contribution relative to polyphenols and roasting products
Source: APC Microbiome Ireland / Adapted from standard coffee composition literature
Polyphenols, Not Caffeine, Reshape the Microbiome
The study, conducted by researchers at APC Microbiome Ireland at University College Cork, enrolled 62 adults in a tightly controlled 5-week protocol: 31 daily coffee drinkers consuming 3–5 cups per day, and 31 non-drinkers. Metagenomic analysis of stool samples revealed consistent directional shifts in bacterial abundance—shifts that appeared identically in both regular and decaffeinated coffee drinkers, ruling out caffeine as the primary driver.
This parallel response to caffeinated and decaffeinated coffee is the study’s most telling observation. Since both forms contain similar concentrations of chlorogenic acids and melanoidins, the data implicate the polyphenol-rich fraction as the active component. According to the research, chlorogenic acids and melanoidins—compounds absent in caffeine—account for 7–10% and approximately 5–8% of coffee by weight, respectively, vastly outweighing caffeine’s 1–2% contribution.
Three Bacterial Shifts: Benefits and Concerns
The study documented three principal microbiome changes in coffee drinkers. First, Cryptobacterium species increased in abundance. These bacteria produce indoles—tryptophan metabolites that activate the aryl hydrocarbon receptor (AhR) on intestinal epithelial cells, a mechanism known to reinforce barrier integrity and modulate innate immune tone. In this context, increased Cryptobacterium may represent a beneficial adaptation supporting intestinal homeostasis.
Second, Eggerthella species expanded in coffee drinkers. Eggerthella bacteria metabolize coffee polyphenols—particularly chlorogenic acids—breaking them down into smaller, bioavailable metabolites that the host can absorb and utilize. This functional specialization suggests a direct link between coffee consumption and microbial capacity to unlock the polyphenol matrix. However, the picture is clinically complex: certain Eggerthella species, especially E. lenta, have been associated with inflammatory flares in inflammatory bowel disease (IBD) and bacteremia in immunocompromised patients, according to prior literature reviewed by the research group. The genus carries a mixed clinical profile—metabolically helpful but potentially pathogenic in specific contexts.
The third finding is less encouraging. Indole-3-propionic acid (IPA)—a tryptophan-derived metabolite produced by bacteria such as Clostridium sporogenes—decreased in coffee drinkers. IPA is anti-inflammatory and supports tight junction integrity in the intestinal barrier. Lower circulating IPA has been linked in the literature to increased type 2 diabetes risk, impaired barrier function, and systemic inflammation. A reduction in IPA is not a known benefit, and may warrant further investigation.
Coffee’s 98–99% non-caffeine composition—particularly chlorogenic acids and melanoidins—drives shifts in gut bacteria including increased Cryptobacterium (barrier-supporting) and Eggerthella (polyphenol-metabolizing) alongside decreased indole-3-propionic acid, a metabolite protective against type 2 diabetes and gut dysfunction.
— APC Microbiome Ireland research group (University College Cork, 5-week controlled study, 2024)
Design Limitations and the Path Forward
The study’s exploratory scope warrants candor about limitations. A sample of 62 participants—split equally between drinkers and non-drinkers—is modest by modern microbiome standards. The 5-week intervention window is relatively short; longer studies are needed to determine whether these shifts stabilize, reverse, or deepen with continued exposure. Behavioral variables (diet, fiber intake, medication use, sleep, stress) were not fully quantified, and the study was not double-blinded, meaning measurement bias cannot be ruled out entirely.
Additionally, while the research identifies bacterial taxa and their predicted metabolic pathways, it does not yet measure actual circulating levels of key metabolites (IPA, indoles, bioavailable polyphenols) in blood or stool. Mechanistic studies linking these microbiome shifts to clinical outcomes remain needed. The decrease in IPA in particular requires scrutiny: if replicated in larger cohorts, it could suggest that daily high-volume coffee consumption carries an under-recognized trade-off, despite coffee’s known associations with lower cardiovascular and all-cause mortality in epidemiological studies.
What this means
Frequently asked questions
Does decaffeinated coffee have the same microbiome effects as regular coffee?
Yes, according to this study. Both regular and decaffeinated coffee produced identical shifts in Cryptobacterium, Eggerthella, and IPA levels, confirming that chlorogenic acids and melanoidins—not caffeine—drive the microbiome changes. This is important for caffeine-sensitive individuals who can still expect to experience coffee’s prebiotic effects through decaf.
Is the decrease in indole-3-propionic acid (IPA) a sign I should stop drinking coffee?
Not necessarily, but it warrants closer study. IPA is linked to lower diabetes risk and better gut barrier function, so a decrease is not immediately favorable. However, this single finding is preliminary (N=62). Before advising patients to change coffee intake, larger, longer-term studies measuring actual blood IPA levels in coffee drinkers and their clinical outcomes are needed. Your clinician can help weigh individual risk factors.
Why is Eggerthella expansion concerning if it metabolizes coffee compounds?
Eggerthella plays two roles. Its metabolic capacity to break down chlorogenic acids is beneficial for polyphenol availability. However, certain Eggerthella species (especially E. lenta) have been implicated in inflammatory bowel disease flares and bloodstream infections in immunocompromised patients. The genus has a mixed clinical profile. This study did not identify which Eggerthella species expanded, so species-level follow-up is essential before drawing conclusions about harm or benefit.
The APC Microbiome Ireland findings open a productive research frontier: understanding coffee not as a caffeine delivery vehicle, but as a complex polyphenol matrix that remodels the human microbiota in measurable, dose-dependent ways. Replication in larger populations, mechanistic studies linking microbiome shifts to clinical endpoints, and stratified analysis by host genetics and metabolic phenotype will be essential to translate these exploratory results into actionable clinical guidance. For now, the evidence suggests that coffee drinkers benefit from polyphenol-driven microbiome remodeling, with the caveat that the full health calculus—including the potentially unfavorable IPA reduction—remains incomplete.
Source: APC Microbiome Ireland research group, University College Cork. Original study summary provided via research institution communication, 2024.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
